The symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence, as may occur in cystitis, prostatitis, urethritis, urethrocystitis and urethrotrigonitis. It is not yet recommended for infants and children under 12 years of age since safety and efficacy studies in this age group are not completed. Although studies in sensitive animals have not shown any potential for teratogenic effects, the drug should only be used during pregnancy if, in the opinion of the physician, the anticipated benefits outweigh any risks. In the event of drowsiness or blurred vision, the patient should not operate a motor vehicle or any machinery, and refrain from participating in activities requiring alertness. There is no known specific antidote.
Treatment is, essentially, symptomatic with close monitoring of vital functions imperative.
In a conscious, alert patient prompt evacuation of the stomach should be performed. When evacuation is complete, observation and further treatment should be made according to the attending physician's assessment of the patient. If overdosage is extreme, or there is delay in removing the drug from the stomach, administration of a parasympathomimetic drug should be considered. In the presence of severe anticholinergic reactions, slow i.v. injection of 1 to 4 mg of physostigmine is indicated, and in case of favorable response, repeated doses may be administered. If marked excitement is observed, diazepam may be given for sedation and control of convulsions.